


Nu.Q[®] Vet Cancer Monitoring Test – in development

- Initial data of 21 dogs presented at the Veterinary Cancer Society Conference, November 2021⁷.


The data demonstrates:

- Nu.Q[®] Vet may serve as a more sensitive measurement of both **minimal residual disease and remission**.
- Circulating nucleosome elevations often precede obvious clinical progression, due to other possible causes of elevations in Nu.Q[®] concentrations it is recommended to have 2 consecutive elevations before altering the treatment or staging protocol in canine cancer patients
- Could be a useful tool to monitor disease response and progression.
- Further data due in 2022.



Case Example - Poppy: 7 year old female spayed St. Bernard
Metastatic Osteosarcoma

Trends in Nucleosome Concentrations during treatment for OSA



Case Example - Buster: 9 year old male neutered Chow Chow mix
Multiple Myeloma

Trends in Nucleosome Concentrations during treatment for Mult. Myeloma

